The Role of 5% Lidocaine Patches in the Pain Control of Hepatocellular Carcinoma Patients Receiving Radiofrequency Ablation
Status:
Completed
Trial end date:
2018-04-30
Target enrollment:
Participant gender:
Summary
Background: This study aims to test whether 5% lidocaine patches can reduce Radiofrequency
ablation-induced pain. Methods: The study will enroll patients with hepatocellular carcinoma
and schedule a radiofrequency ablation procedure. 200 patients will be invited to allocate
randomly into study or control groups: pretreatment with a 5% lidocaine patch (LidotopⓇ)
(Group A); pretreatment with a placebo patch (Group B); The skin patch is applied before
Radiofrequency ablation (RFA) while admission, and is changed every day till discharge. Pain
severity is evaluated by a visual analog scale using a 10-point scale recorded by a study
nurse before RFA and after the procedure. The demographic data, hepatocellular carcinoma
characteristics, analgesics usage, patient satisfaction with pain control, and visual analog
scale will be compared between the two groups. Anticipated results: Pretreatment with 5%
lidocaine patches is an effective and straight method of reducing Radiofrequency
ablation-induced pain to reduce analgesics usage and improve patient satisfaction with pain
control.